Galderma Laboratories v. Teva Pharmaceuticals USA, No. 19-2396 (Fed. Cir. Jan. 29, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This patent infringement suit arises from the filing of Teva Pharmaceuticals USA, Inc. ’s (“Teva’s”) Abbreviated New Drug Application (“ANDA”) No. 210019. In its ANDA, Teva seeks approval to market a generic version of Soolantra®, a pharmaceutical product marketed by Plain- tiffs Galderma Laboratories, L.P., Galderma S.A., and Nestlé Skin Health S.A. (collectively, “Galderma”). Follow- ing a bench trial, the U.S. District Court for the District of Delaware entered final judgment for Teva, holding that the asserted claims of U.S. Patent Nos.